Trial data on both established and novel transcatheter valve technologies were among the big device stories coming out of this year's EuroPCR conference in Paris, which also featured new data on bioresorbable coronary stents, and additional findings from the recent major studies of coronary evaluation with instantaneous wave-free ratio.
Early in the meeting, results from REPRISE III support Boston Scientific Corp.'s Lotus transcatheter aortic valve in a high-risk patients and puts the repositionable valve on track...